Neurocrine Bio. (NBIX) PT Lowered to $154 at Piper Sandler

May 6, 2025 8:37 AM EDT Send to a Friend
Piper Sandler analyst David Amsellem lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $154.00 (from $160.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login